Incyte Biosciences UK’s Opzelura (ruxolitinib) cream has been approved for reimbursement for eligible patients with non-segmental vitiligo by the National Institute for Health and Care Excellence ...

Commit Biologics, a biotech company pioneering complement system activation, has appointed Thomas Montgomery Andresen as Chief Executive Officer (CEO), effective 16 March 2026. Thomas, a biotech ...

The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...

There’s a clear gap: output is rising, but engagement isn’t. This often happens because many strategies focus on HCPs’ ...

Medical Affairs is operating at a pivotal moment. Expectations have expanded rapidly – deeper scientific exchange, sharper ...

Patients should never be treated as passive recipients of AI-enabled outputs. The enduring principles of patient-centred research show that it is precisely the active engagement of patients in the ...

Johnson & Johnson (J&J) has announced US FDA approval for Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat adults with relapsed or refractory multiple ...

Johnson & Johnson’s (J&J) nipocalimab, a potential immunoselective investigational treatment for adults with systemic lupus ...

In our 20 years of experience in the healthcare industry, THE PLANNING SHOP international has worked in almost every therapeutic area. We may not be the only specialist healthcare market research ...

Stop pushing content at a burnt-out audience and start creating "Digital Magnetism." Join Impetus Digital to unlock the 2026 ...

UK biotech N4 Pharma, a company developing a gene delivery system to enable advanced therapies for cancer and other diseases, ...

Novo Nordisk has announced it will invest 432m euros in its facility in Ireland. The tabletting facility, in Monksland, Athlone, will provide significant additional manufacturing capacity for current ...